Explore the Agenda
9:00 am Check In & Light Breakfast
Workshop A
9:30 am Improving Patient Access to TIL Therapies by Coordinating Clinical Trial Operations to Enable Earlier Treatment & Broader Reach
Delivering TIL therapies at scale requires close collaboration between community physicians’ specialist centers, surgeons and clinical trial teams rather than changes by any single group alone. As clinical evidence matures and trials expand into earlier lines and broader populations, the challenge is aligning referral timing, clinician education, hospital resources, and trial logistics. This workshop focuses on shared problem solving across clinical and operational roles to support access while maintaining high standards of care and trial integrity.
Key questions addressed in this workshop:
- How can referral pathways be strengthened through earlier collaboration with community oncologists and shared visibility of patient flow?
- What practical approaches help clinicians, surgeons, and trial teams align around beds surgery slots and manufacturing availability?
- How can education reimbursement considerations and trial participation work together to support treatment beyond specialist centers?
- How should clinical trials be designed to reflect real-world workflows while enabling access expansion and operational feasibility?
12:30 pm Lunch & Networking
Workshop B
1:30 pm Trade-Offs Between Specificity, Potency, Scalability, & Safety in Current TIL Approaches
As the field moves beyond melanoma, the need for optimized efficacy and safety is forcing a rethink of manufacturing strategies and delivery strategies.
This workshop addresses the growing recognition that current TIL strategies involve bulk TIL expansion, diluting tumor reactive potential and requiring high dose IL-2 for efficacy.
Key questions addressed in this workshop:
- Which tumor-infiltrating lymphocyte subsets are truly reactive rather than expanded bystanders?
- Do selection approaches such as PD-1 or neoantigen targeting enrich potency or accelerate exhaustion?
• How can next-generation approaches optimize safety vs. efficacy?